Compare GIC & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIC | TRVI |
|---|---|---|
| Founded | 1949 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 1996 | 2019 |
| Metric | GIC | TRVI |
|---|---|---|
| Price | $31.77 | $11.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $21.55 |
| AVG Volume (30 Days) | 86.2K | ★ 1.2M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.55% | N/A |
| EPS Growth | 17.09 | ★ 31.91 |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $1,379,100,000.00 | N/A |
| Revenue This Year | $5.72 | N/A |
| Revenue Next Year | $4.46 | N/A |
| P/E Ratio | $17.04 | ★ N/A |
| Revenue Growth | ★ 4.80 | N/A |
| 52 Week Low | $20.79 | $4.85 |
| 52 Week High | $38.53 | $14.39 |
| Indicator | GIC | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 55.05 | 54.43 |
| Support Level | $29.40 | $10.07 |
| Resistance Level | $32.16 | $12.11 |
| Average True Range (ATR) | 0.94 | 0.73 |
| MACD | 0.09 | 0.06 |
| Stochastic Oscillator | 85.01 | 66.23 |
Global Industrial Co is a value-added industrial distributor. The company distributes a wide range of industrial and maintenance, repair, and operations (MRO) products to customers across North America, including storage and shelving, safety and security, carts and trucks, HVAC and fans, furniture and decor, material handling, janitorial and facility maintenance, workbenches and shop desks, tools and instruments, plumbing and pumps, office and school supplies, packaging and shipping, lighting and electrical, food service and retail, medical and laboratory, motors and power transmission, building supplies, machining, fasteners and hardware, vehicle maintenance, and raw materials.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.